Neuralink Expands Brain Implant Trials with 12 Global Patients 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
NASA and SpaceX Target Crew-11 Undocking From ISS Amid Medical Concern 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Asian Stocks Slip as Tech Rout Deepens, Japan Steadies Ahead of Election 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
China Extends Gold Buying Streak as Reserves Surge Despite Volatile Prices 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
